ABBV US00287Y1091

Report

Delayed Nyse - 12/03 04:10:00 pm
118.85	USD		+1.69%

12/03	FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly	RE
12/03	AbbVie Labeling for Rheumatoid Arthritis Drug Rinvoq Updated to Include Cancer, Cardiovascular Risks	MT
12/03	AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.	PR

Summary

Quotes 5-day view Delayed Quote.

Delayed Nyse

11/29/2021	11/30/2021	12/01/2021	12/02/2021	12/03/2021	Date
116.89(c)	115.28(c)	115.91(c)	116.87(c)	118.85(c)	Last
4 372 526	8 172 099	6 293 338	4 919 820	6 415 009	Volume
+0.33%	-1.38%	+0.55%	+0.83%	+1.69%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2021	56 248 M - -
Net income 2021	11 044 M - -
Net Debt 2021	63 490 M - -
P/E ratio 2021	19,1x
Yield 2021	4,38%

Sales 2022	59 786 M - -
Net income 2022	14 980 M - -
Net Debt 2022	50 649 M - -
P/E ratio 2022	13,3x
Yield 2022	4,71%

Capitalization	210 B 210 B -
EV / Sales 2021	4,86x
EV / Sales 2022	4,36x
Nbr of Employees	50 000
Free-Float	98,0%

More Financials

Company

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human...

Sector

Pharmaceuticals

Calendar

12/11

Presentation

More about the company

Ratings of AbbVie Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

All news about ABBVIE INC.

12/03	FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly	RE
12/03	AbbVie Labeling for Rheumatoid Arthritis Drug Rinvoq Updated to Include Cancer, Cardiov..	MT
12/03	AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthri..	PR
11/30	AbbVie Seeks European Approval for Risankizumab in Moderate to Severe Crohn's Disease	MT
11/30	ABBVIE : The Alliance for Endometriosis Survey Reveals Actions Needed to Improve the Endom..	PU
11/30	AbbVie Submits Europe Application for Risankizumab for Crohn's Disease	DJ
11/30	AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Di..	PR
11/30	AbbVie Submits Application for Risankizumab (SKYRIZI?) in Moderate to Severe Crohn's Di..	CI
11/24	Truist Adjusts Price Target on AbbVie to $135 From $118, Maintains Buy Rating	MT
11/24	NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-	DJ
11/23	AbbVie Shares Rise After Societe Generale's Upgrade, Price Target Hike	MT
11/23	Societe Generale Upgrades AbbVie to Buy from Hold, Raises Price Target to $172 From $11..	MT
11/23	WALL STREET STOCK EXCHANGE : The Fed cannot stop Covid
11/23	AbbVie to Present at the Evercore ISI Conference	PR
11/23	AbbVie to Present at the Piper Sandler Healthcare Conference	PR

More news

News in other languages on ABBVIE INC.

12/03	Mise à jour de l'étiquetage de Rinvoq, le médicament d'AbbVie contre la polyarthrite rh..
11/23	Les actions d'AbbVie augmentent après la mise à jour de la Société Générale et la hauss..
11/17	Skyrizi d'AbbVie obtient l'autorisation de l'Union européenne pour le rhumatisme psoria..
11/11	INVENTIVA : hausse de la trésorerie au 30 septembre malgré des coûts de R&D plus élevés
11/10	AbbVie et l'Université de Chicago prolongent leur partenariat de recherche en oncologie..

More news

Analyst Recommendations on ABBVIE INC.

11/24	Truist Adjusts Price Target on AbbVie to $135 From $118, Maintains Buy Rating	MT
11/23	Societe Generale Upgrades AbbVie to Buy from Hold, Raises Price Target to $172 From $11..	MT
11/23	ANALYST RECOMMENDATIONS : AbbVie, AIG, CBRE, Stoneco, Vonage...

More recommendations

Provided by Scoopnest.com

Analysis

Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion